筋弛緩薬の世界市場レポート 2025年

筋弛緩薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.1％で70億5,000万米ドルに成長します。予測期間の成長は、集学的疼痛管理アプローチ、人口の高齢化と慢性疾患、標的療法の調査、非薬理学的疼痛緩和への注力、疼痛管理療法の進歩に起因すると考えられます。予測期間における主な動向としては、副作用プロファイルの進歩、個別化医療アプローチ、代替療法の研究、疼痛管理プロトコルへの筋弛緩薬の統合、ボツリヌス毒素注射の登場などが挙げられます。

筋弛緩薬市場は、老年人口の拡大が大きな原動力となって成長が見込まれます。これらの薬剤は65歳以上の高齢者を対象としており、痛みを和らげたり、筋骨格系の障害に悩むことの多いこの層を鎮静化したりします。例えば、2022年10月現在、世界保健機関（WHO）は、60歳以上の人口が世界的に急増し、2020年の10億人から2022年には14億人に達すると予測しています。また、2030年には世界の6人に1人が60歳以上になると予測されています。この人口動態の変化は、筋弛緩薬市場の成長を大きく促進する要因となっています。

筋弛緩薬市場の成長予測は、スポーツ傷害の増加にも起因しています。これらの傷害には、スポーツ活動に従事することで生じるさまざまな物理的外傷が含まれ、筋肉、骨、腱、靭帯、関節に影響を及ぼします。筋弛緩剤は、スポーツ活動中に発生する筋肉の痙攣や傷害の管理に不可欠です。例えば、全米安全評議会が2022年9月に発表したデータによると、米国で報告されたスポーツおよびレクリエーションによる傷害は、2021年に20％急増し、2022年にはさらに12％増加しました。2022年、スポーツやレクリエーション用具に関連した傷害で救急診療部が治療した人数は合計360万人でした。このようなスポーツ関連の傷害の増加は、筋弛緩薬市場を牽引する構えです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の筋弛緩薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の筋弛緩薬市場：成長率分析
• 世界の筋弛緩薬市場の実績：規模と成長, 2019-2024
• 世界の筋弛緩薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の筋弛緩薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の筋弛緩薬市場：薬剤タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フェイシャル筋弛緩薬
• スケルタル筋弛緩薬
• 神経筋遮断薬
• 世界の筋弛緩薬市場：製剤別、実績と予測, 2019-2024, 2024-2029F, 2034F
• シクロベンザプリン
• カリソプロドール
• クロルゾキサゾン
• メタキサロン
• メトカルバモール
• バクロフェン
• チザニジン
• オルフェナドリン
• ダントロレン
• 世界の筋弛緩薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 注射可能
• スプレー
• 軟膏
• 世界の筋弛緩薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 在宅ケア
• 専門クリニック
• その他のエンドユーザー
• 世界の筋弛緩薬市場：顔面筋弛緩薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ボツリヌス毒素
• ディスポート
• ゼオミン
• 世界の筋弛緩薬市場：骨格筋弛緩薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 中枢性筋弛緩薬
• 末梢作用型筋弛緩薬
• 世界の筋弛緩薬市場、神経筋遮断薬のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非脱分極性剤
• 脱分極剤

第7章 地域別・国別分析

• 世界の筋弛緩薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の筋弛緩薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 筋弛緩薬市場：競合情勢
• 筋弛緩薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Ipsen Pharma SA Overview, Products and Services, Strategy and Financial Analysis
  • Teijin Limited Overview, Products and Services, Strategy and Financial Analysis
  • Par Pharmaceutical Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Orient Phaarma Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Accord Healthcare Ltd.
• Amneal Pharmaceuticals LLC
• Fresenius Kabi India Pvt. Ltd.
• Aurobindo Pharma Ltd.
• Mylan NV
• Hikma Pharmaceuticals PLC
• Akorn Incorporated
• Merck & Co. Inc.
• Teva Pharmaceuticals Industries Ltd.
• Lifesciences Limited
• Neurana Pharmaceuticals Inc.
• Dr. Reddy's Laboratories
• Lannett Company Inc.
• Unichem Laboratories

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 筋弛緩薬市場2029：新たな機会を提供する国
• 筋弛緩薬市場2029：新たな機会を提供するセグメント
• 筋弛緩薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Muscle relaxants are pharmaceuticals utilized to alleviate muscle spasms stemming from neurological conditions, primarily employed to manage muscle pain.

The primary categories of muscle relaxant drugs include facial muscle relaxants, skeletal muscle relaxants, and neuromuscular blocking agents. Facial muscle relaxants specifically target facial spasms and cramps. These medications come in various formulations such as cyclobenzaprine, carisoprodol, chlorzoxazone, metaxalone, methocarbamol, baclofen, tizanidine, orphenadrine, and dantrolene, administered orally, via injection, spray, or ointment. These drugs cater to diverse end-users, encompassing hospitals, home care settings, specialty clinics, and others.

The muscle relaxant drugs market research report is one of a series of new reports from The Business Research Company that provides muscle relaxant drugs market statistics, including the muscle relaxant drugs industry's global market size, regional shares, competitors with a muscle relaxant drugs market share, detailed muscle relaxant drugs market segments, market trends and opportunities, and any further data you may need to thrive in the muscle relaxant drugs industry. This muscle relaxant drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The muscle relaxant drugs market size has grown strongly in recent years. It will grow from $4.77 billion in 2024 to $5.16 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to shift in treatment approaches, chronic pain management, pharmaceutical innovation in drug formulations, rise in surgical procedures, expansion in physical rehabilitation practices.

The muscle relaxant drugs market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to multidisciplinary pain management approaches, aging population and chronic conditions, research in targeted therapies, focus on non-pharmacological pain relief, advancements in pain management therapies. Major trends in the forecast period include advancements in side effect profiles, personalized medicine approach, research in alternative therapies, integration of muscle relaxants in pain management protocols, advent of botulinum toxin injections.

The muscle relaxant drugs market is expected to experience growth, driven significantly by the expanding geriatric population. These drugs cater to older adults aged 65 and above, relieving pain and sedating this demographic, which often grapples with musculoskeletal disorders. For instance, as of October 2022, the World Health Organization projected a global surge in the population aged 60 and older, expecting it to reach 1.4 billion by 2022, up from 1 billion in 2020. Projections also indicate that by 2030, roughly one out of every six individuals worldwide will be 60 years or older. This demographic shift is a substantial driver for the muscle relaxant drugs market's growth.

Anticipated growth in the muscle relaxant drugs market is also attributed to the increasing occurrences of sports injuries. These injuries encompass a spectrum of physical traumas arising from engaging in athletic activities, affecting muscles, bones, tendons, ligaments, and joints. Muscle relaxants are integral in managing muscle spasms and injuries incurred during sports activities. For example, according to data released by the National Safety Council in September 2022, reported sports and recreational injuries in the US surged by 20% in 2021 and a subsequent 12% in 2022. Emergency departments treated a total of 3.6 million individuals for injuries related to sports and recreational equipment in 2022. This rise in sports-related injuries is poised to drive the muscle relaxant drugs market.

The muscle relaxant drugs market is witnessing a significant trend characterized by product innovations. Leading market players are actively developing novel drugs tailored for specific medical applications. These innovations include generic versions of muscle relaxant drugs, formulations catering to animal use, and drugs allowing flexible and personalized dosing. Take, for instance, the launch of LYVISPAH by Amneal Pharmaceuticals Inc. in June 2022. This baclofen oral granule product, approved by the US FDA, targets spasticity associated with multiple sclerosis and spinal cord disorders. The granules offer flexible dosing options and accommodate patients experiencing difficulties swallowing pills, presenting a novel alternative in muscle relaxant therapy.

Within the muscle relaxant drugs market, major companies are concentrating on introducing cost-effective alternatives, such as generic muscle relaxant injectables, to gain a competitive edge. These generic injectables replicate the active ingredients found in branded counterparts and are administered via injection. For instance, Lupin Limited launched Rocuronium Bromide Injection in November 2023, following FDA approval. This generic version acts as a substitute for Zemuron Injection by Organon USA Inc., aiding in skeletal muscle relaxation during surgeries or mechanical ventilation. It caters to both inpatients and outpatients and is utilized as an adjunct to general anesthesia.

In June 2023, Corona Remedies completed the acquisition of the muscle relaxant brand Myoril from Sanofi India for INR 234 crore ($31 million). This strategic move fortifies CORONA Remedies' position in the expanding Indian muscle relaxant market. Myoril, with annual sales of INR 38 crore ($5 million) and a growth rate of 6.8%, contributes significantly to Corona Remedies' market presence. Sanofi India, a prominent healthcare and pharmaceutical company specializing in muscle relaxant drugs, facilitated this acquisition.

Major companies operating in the muscle relaxant drugs market are Pfizer Inc., Ipsen Pharma SA, Teijin Limited, Par Pharmaceutical Companies Inc., Orient Phaarma Co. Ltd., Novartis AG, Accord Healthcare Ltd., Amneal Pharmaceuticals LLC, Fresenius Kabi India Pvt. Ltd., Aurobindo Pharma Ltd., Mylan NV, Hikma Pharmaceuticals PLC, Akorn Incorporated, Merck & Co. Inc., Teva Pharmaceuticals Industries Ltd., Lifesciences Limited, Neurana Pharmaceuticals Inc., Dr. Reddy's Laboratories, Lannett Company Inc., Unichem Laboratories, SteriMax Inc., Endo Pharmaceuticals Inc., Abbvie Inc., Merz Pharmaceuticals LLC, Vertical Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Eisai Co. Ltd., Metacel Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Lupin Ltd., Intas Pharmaceuticals Ltd., Alkem Laboratories Ltd.

North America was the largest region in the muscle relaxant drugs market share in 2024. The regions covered in the muscle relaxant drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the muscle relaxant drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The muscle relaxant drugs market consists of sales of antispasmodics, benzodiazepines and nonbenzodiazepines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Muscle Relaxant Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on muscle relaxant drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for muscle relaxant drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The muscle relaxant drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Facial Muscle Relaxant Drugs; Skeletal Muscle Relaxant Drugs; Neuromuscular Blocking Agents
• 2) By Formulation: Cyclobenzaprine; Carisoprodol; Chlorzoxazone; Metaxalone; Methocarbamol; Baclofen; Tizanidine; Orphenadrine; Dantrolene
• 3) By Route Of Administration: Oral; Injectable; Spray; Ointment
• 4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Facial Muscle Relaxant Drugs: Botulinum Toxin; Dysport; Xeomin
• 2) By Skeletal Muscle Relaxant Drugs: Centrally Acting Muscle Relaxants; Peripherally Acting Muscle Relaxants
• 3) By Neuromuscular Blocking Agents: Non-Depolarizing Agents; Depolarizing Agents
• Companies Mentioned: Pfizer Inc.; Ipsen Pharma SA; Teijin Limited; Par Pharmaceutical Companies Inc.; Orient Phaarma Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Muscle Relaxant Drugs Market Characteristics

3. Muscle Relaxant Drugs Market Trends And Strategies

4. Muscle Relaxant Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Muscle Relaxant Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Muscle Relaxant Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Muscle Relaxant Drugs Market Growth Rate Analysis
• 5.4. Global Muscle Relaxant Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Muscle Relaxant Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Muscle Relaxant Drugs Total Addressable Market (TAM)

6. Muscle Relaxant Drugs Market Segmentation

• 6.1. Global Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Facial Muscle Relaxant Drugs
• Skeletal Muscle Relaxant Drugs
• Neuromuscular Blocking Agents
• 6.2. Global Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cyclobenzaprine
• Carisoprodol
• Chlorzoxazone
• Metaxalone
• Methocarbamol
• Baclofen
• Tizanidine
• Orphenadrine
• Dantrolene
• 6.3. Global Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Spray
• Ointment
• 6.4. Global Muscle Relaxant Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Speciality Clinics
• Other End-Users
• 6.5. Global Muscle Relaxant Drugs Market, Sub-Segmentation Of Facial Muscle Relaxant Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Botulinum Toxin
• Dysport
• Xeomin
• 6.6. Global Muscle Relaxant Drugs Market, Sub-Segmentation Of Skeletal Muscle Relaxant Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Centrally Acting Muscle Relaxants
• Peripherally Acting Muscle Relaxants
• 6.7. Global Muscle Relaxant Drugs Market, Sub-Segmentation Of Neuromuscular Blocking Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Depolarizing Agents
• Depolarizing Agents

7. Muscle Relaxant Drugs Market Regional And Country Analysis

• 7.1. Global Muscle Relaxant Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Muscle Relaxant Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Muscle Relaxant Drugs Market

• 8.1. Asia-Pacific Muscle Relaxant Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Muscle Relaxant Drugs Market

• 9.1. China Muscle Relaxant Drugs Market Overview
• 9.2. China Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Muscle Relaxant Drugs Market

• 10.1. India Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Muscle Relaxant Drugs Market

• 11.1. Japan Muscle Relaxant Drugs Market Overview
• 11.2. Japan Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Muscle Relaxant Drugs Market

• 12.1. Australia Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Muscle Relaxant Drugs Market

• 13.1. Indonesia Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Muscle Relaxant Drugs Market

• 14.1. South Korea Muscle Relaxant Drugs Market Overview
• 14.2. South Korea Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Muscle Relaxant Drugs Market

• 15.1. Western Europe Muscle Relaxant Drugs Market Overview
• 15.2. Western Europe Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Muscle Relaxant Drugs Market

• 16.1. UK Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Muscle Relaxant Drugs Market

• 17.1. Germany Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Muscle Relaxant Drugs Market

• 18.1. France Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Muscle Relaxant Drugs Market

• 19.1. Italy Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Muscle Relaxant Drugs Market

• 20.1. Spain Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Muscle Relaxant Drugs Market

• 21.1. Eastern Europe Muscle Relaxant Drugs Market Overview
• 21.2. Eastern Europe Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Muscle Relaxant Drugs Market

• 22.1. Russia Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Muscle Relaxant Drugs Market

• 23.1. North America Muscle Relaxant Drugs Market Overview
• 23.2. North America Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Muscle Relaxant Drugs Market

• 24.1. USA Muscle Relaxant Drugs Market Overview
• 24.2. USA Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Muscle Relaxant Drugs Market

• 25.1. Canada Muscle Relaxant Drugs Market Overview
• 25.2. Canada Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Muscle Relaxant Drugs Market

• 26.1. South America Muscle Relaxant Drugs Market Overview
• 26.2. South America Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Muscle Relaxant Drugs Market

• 27.1. Brazil Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Muscle Relaxant Drugs Market

• 28.1. Middle East Muscle Relaxant Drugs Market Overview
• 28.2. Middle East Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Muscle Relaxant Drugs Market

• 29.1. Africa Muscle Relaxant Drugs Market Overview
• 29.2. Africa Muscle Relaxant Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Muscle Relaxant Drugs Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Muscle Relaxant Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Muscle Relaxant Drugs Market Competitive Landscape And Company Profiles

• 30.1. Muscle Relaxant Drugs Market Competitive Landscape
• 30.2. Muscle Relaxant Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Ipsen Pharma SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teijin Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Par Pharmaceutical Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Orient Phaarma Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Muscle Relaxant Drugs Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Accord Healthcare Ltd.
• 31.3. Amneal Pharmaceuticals LLC
• 31.4. Fresenius Kabi India Pvt. Ltd.
• 31.5. Aurobindo Pharma Ltd.
• 31.6. Mylan NV
• 31.7. Hikma Pharmaceuticals PLC
• 31.8. Akorn Incorporated
• 31.9. Merck & Co. Inc.
• 31.10. Teva Pharmaceuticals Industries Ltd.
• 31.11. Lifesciences Limited
• 31.12. Neurana Pharmaceuticals Inc.
• 31.13. Dr. Reddy's Laboratories
• 31.14. Lannett Company Inc.
• 31.15. Unichem Laboratories

32. Global Muscle Relaxant Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Muscle Relaxant Drugs Market

34. Recent Developments In The Muscle Relaxant Drugs Market

35. Muscle Relaxant Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Muscle Relaxant Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Muscle Relaxant Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Muscle Relaxant Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer